Multi-arm PEG Derivative Synthesis via Segmented Core
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for synthesizing multi-arm single-molecular weight polyethylene glycol (PEG) products face challenges in scalability and cost due to difficulties in synthesis, resulting in high impurity levels and variability in molecular weight distribution.
Innovation Solution
Development of a multi-arm single molecular weight polyethylene glycol and its active derivative, characterized by specific core structures, linking groups, and terminal groups, which can be used to prepare high-purity gel materials and pharmaceutical conjugates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional methods are used to synthesize multi-arm PEG products, then production scale can be increased, but molecular weight distribution becomes broad and impurity levels increase
Solution Approach 1:
The synthesis process is divided into multiple sequential steps: first forming a core structure with multiple reactive groups, then progressively adding PEG chains one at a time through controlled reaction conditions. This segmentation allows each step to be optimized independently, maintaining narrow molecular weight distribution while enabling scale-up to multi-kilogram productions.
Solution Approach 2:
A core structure with predetermined multiple reactive groups (such as pentaerythritol with four hydroxyl groups) is prepared in advance before PEG chain attachment. This preliminary preparation ensures that each PEG chain attaches to a specific position on the core, preventing random cross-linking and maintaining uniform molecular weight distribution during scaled production.
2Ease of manufacture
If conventional synthesis methods are used for multi-arm PEG, then production cost can be reduced, but product purity decreases due to high impurity levels
Solution Approach 1:
A core structure with multiple identical reactive groups serves as an intermediary that directs the attachment of PEG chains in a controlled manner. This intermediary approach ensures that each PEG chain attaches at predetermined positions, minimizing side reactions and impurity formation, thereby achieving high purity (>95%) products at scalable production levels.
Solution Approach 2:
Reaction parameters such as temperature, solvent composition, and reagent ratios are precisely controlled and optimized for each synthesis step. By maintaining specific parameter ranges (e.g., temperature control within ±2°C, specific solvent ratios), the process achieves high purity products while remaining cost-effective for scaled production.
3Quantity of substance
If multi-arm PEG products are synthesized to increase drug loading per unit, then therapeutic efficacy improves, but synthesis difficulty and cost increase
Solution Approach 1:
The core structure is designed with multiple identical reactive groups that can each attach a PEG-drug conjugate module. This universal design allows the same core structure to be used for producing multi-arm PEG products with different arm numbers (4-arm, 8-arm, 12-arm, etc.) by simply adjusting the number of reaction cycles, thereby increasing drug loading without proportionally increasing synthesis complexity.
Solution Approach 2:
The synthesis process uses continuous sequential addition of PEG chains to the core structure without isolating intermediate products. Each PEG chain is added in succession under the same optimized reaction conditions, maintaining continuous productive action and avoiding the complexity of multiple isolation and purification steps, thus enabling high drug loading with manageable synthesis complexity.
Data Source
AI summary
Being used for drug modification, the multi-arm single molecular weight polyethylene glycol active derivative provided herein can effectively improve the solubility, stability, and immunogenicity of the drugs, improve the absorption of the drugs in vivo, prolong the half-life of the drugs, and increase bioavailability, enhance efficacy, and reduce toxic and side effects of the drugs. A gel formed from the multi-arm single molecular weight polyethylene glycol active derivative provided herein can be used for the preparation of controlled release drugs so as to prolong the action time of the drugs, thereby reducing the number of administrations and improving patient compliance.